(betaAla(8))NKA(4-10),
8-beta-Ala-neurokinin A (4-10),
bAla-NKA (4-10),
neurokinin A (4-10), beta-Ala(8)-,
neurokinin A (4-10), beta-alanine(8)-,
122063-01-8,
[bAla8]-Neurokinin A(4-10),
Asp-Ser-Phe-Val-beta-Ala-Leu-Met-NH2,
CHEMBL1875296,
(betaAla8)neurokinin A(4-10),
HY-P1031,
MEN 10210,
ZINC95543647,
AKOS024456720,
CS-7598,
NCGC00167336-01,
[|A-Ala8]-Neurokinin A Fragment 4-10,
H-ASP-SER-PHE-VAL-BETA-ALA-LEU-MET-NH2,
C-56429,
[beta-Ala8]-Neurokinin A Fragment 4-10, >=97% (HPLC), powder,
L-Methioninamide,l-a-aspartyl-L-seryl-L-phenylalanyl-L-valyl-b-alanyl-L-leucyl-,
(5S,8S,15S,18S,21S,24S)-24-amino-18-benzyl-5-carbamoyl-21-(hydroxymethyl)-8-isobutyl-15-isopropyl-7,10,14,17,20,23-hexaoxo-2-thia-6,9,13,16,19,22-hexaazahexacosan-26-oic acid,
Bala-nka (4-10),
(Betaala(8))nka(4-10),
C35H56N8O10S,
CKNPSJOMUQBPLA-WTWMNNMUSA-N,
8-beta-Ala-neurokinin A (4-10),
neurokinin A (4-10), beta-Ala(8)-,
C35-H56-N8-O10-S,
CID9987795,
Neurokinin A (4-10), beta-alanine(8)-,
L-Methioninamide, L-alpha-aspartyl-L-seryl-L-phenylalanyl-L-valyl-beta-alanyl-L-leucyl-,